FMP
NASDAQ
5.14 USD
0.02 (0.389%)
Dr. Rachel E. Haurwitz Ph.D.
Healthcare
Biotechnology
https://cariboubio.com
NASDAQ
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, a...
0001619856
US1420381089
142038108
2929 7th Street
510 982 6030
US
158
Jul 23, 2021
0001619856
NASDAQ
Biotechnology
Healthcare
142038108
US1420381089
US
5.14
2.59
1.62M
464.22M
-
3.44-8.59
-0.03
-
-
-
-
-3.72
-
https://cariboubio.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.